信立泰 (002294)

Shenzhen Salubris Pharmaceuticals Co., Ltd.

ASZ

Tags

MSCI Mid Cap IndexGeneric DrugsInnovative DrugsChemical PharmaceuticalsFund Heavy PositionsCCTV 50 IndexPlanned Reduction of HoldingsHigh-Performing StocksChina Securities Finance and Central Huijin HoldingsNon-Cyclical StocksHigh-Dividend StocksShenzhen ConnectSZSE 300 IndexSZSE Growth IndexTech 100 IndexCSFC HoldingsPharma & BiotechSZSE Defensive 50 IndexConsumer Services IndexSME Board Emerging IndexSZSE Enterprises Composite IndexGreater Bay Area IndexSZSE Medicine Equal Weight IndexBrand Engineering IndexInnovation Demonstration IndexInnovation Engine IndexPharmaceutical IndexZhongchuang Equal Weight IndexShenzhen A-Share Pharmaceutical IndexCCTV Innovation IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexSHS Technology 100 IndexZhongchuang Growth IndexSZSE 1000 IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnLarge & Mid-cap IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexMSCIFTSE Russell ConceptHuijin ConceptLarge-cap Blue-chipGene EditingPension Industry IndexSME Board Composite IndexSHS Greater Bay Area IndexSZSE Selected IndexCS High-end Manufacturing IndexZhongchuang 100 Return IndexSZSE Technology IndexSHS Innovative Drugs IndexSZSE ChiNext 100 IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI IndexCCTV Governance IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCS Pearl River Delta IndexSZSE Private Enterprises IndexChina United Quality Growth IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexSZSE Pharmaceutical 50 IndexSME Board Low Volatility IndexSZSE 300 Equal Weight IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexSME Board Performance IndexCSI 700 IndexMid-small Cap IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexCSI 500 Growth Innovation IndexPharmaceutical 50 Strategy IndexSZSE 200 Return IndexSZSE 200 IndexMid-cap Low Volatility IndexZhongchuang 400 IndexCS Innovative Drugs IndexCR New Momentum IndexJuchao Mid-cap IndexShenzhen Technology IndexSZSE 500 IndexCSI 500 ESG IndexGuangdong

K-Line Chart

No K-line data available

Company NameShenzhen Salubris Pharmaceuticals Co., Ltd.
Listing Date2009-09-10
Issue Price41.98RMB
Registered Capital111481.653510k RMB
Legal RepresentativeKevin Sing Ye
Registered AddressArea A, 4th Floor, 289 Digital Peninsula, No. 2 Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen City, Guangdong Province
IndustryChemical Pharmaceuticals
Main BusinessIncluding research and development, production of chemical APIs, powder injections, tablets, capsules; production and sales of genetic engineering drugs; production of Class III 6846 implant materials and artificial organs [within the scope approved by the (Medical Device Manufacturing Enterprise License)], sales of self-produced products; R&D of medical devices; R&D, technology transfer, and technical consulting of pharmaceuticals; R&D, technical consulting, technical services, and technology transfer of biotechnology.
Company ProfileShenzhen Salubris Pharmaceuticals Co., Ltd. is a comprehensive pharmaceutical group integrating R&D, production, and sales of pharmaceutical products. Since 2013, Salubris has been selected for multiple consecutive years among the "Top 20 Competitive Listed Pharmaceutical Companies in China". In 2017 and 2018, it was consecutively selected among the "Top 10 Listed Pharmaceutical Companies in China by R&D Innovation Capability". The antiplatelet aggregation drug Taijia (Clopidogrel Bisulfate Tablets) passed EU GMP certification in 2012 and won the "China Patent Gold Award" in 2016. Additionally, the company possesses multiple proprietary intellectual property products, such as the Class 1 ARB antihypertensive new drug "Xinlitan" and the chemical drug "Taijianing".

Stock Details

1. Key Indicators

  • Total Shares(W): 111481.65
  • Circulating A-Shares(W): 111456.57
  • Earnings Per Share(RMB): 0.5200
  • Net Assets Per Share(RMB): 7.8690
  • Operating Revenue(W RMB): 324129.68
  • Total Profit(W RMB): 65069.88
  • Net Profit Attributable to Parent(W RMB): 58070.66
  • Net Profit Growth Rate(%): 13.93
  • Weighted Return on Equity(%): 6.6700
  • Operating Cash Flow Per Share(RMB): 0.6970
  • Undistributed Profit Per Share(RMB): 4.5921
  • Capital Reserve Per Share(RMB): 1.7692

2. Main Business

The main business covers:

  • Research, production, and sales of pharmaceuticals and medical devices.
  • Patent licensing.

3. Company Basic Information

  • Company Name: Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • Listing Date: 2009-09-10
  • Industry: Pharmaceutical Manufacturing
  • Address: 37th Floor, Greenview Plaza, 6009 Shennan Avenue, Futian District, Shenzhen, Guangdong Province
  • Website: www.salubris.com
  • Company Profile: Shenzhen Salubris Pharmaceuticals Co., Ltd. is a foreign-invested joint-stock company established on June 29, 2007, through the overall transformation of Shenzhen Salubris Pharmaceutical Co., Ltd., approved by the Ministry of Commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Salubris Pharmaceutical Co., Ltd. General Legal Person 63527.94 57.00
2 China Europe Healthcare Hybrid Securities Investment Fund A Class Fund 2717.92 2.44
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1892.12 1.70
4 Shenzhen Runfu Investment Development Co., Ltd. General Legal Person 1546.60 1.39
5 Central Huijin Asset Management Co., Ltd. Special Legal Person 1406.67 1.26
6 Shenzhen Salubris Pharmaceuticals Co., Ltd. - Phase III Employee Stock Ownership Plan Asset Management Plan 1340.89 1.20
7 ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund A Class Fund 1280.00 1.15
8 National Social Security Fund 114 Portfolio Social Security Fund 992.75 0.89
9 ChinaAMC Innovation Medicine Theme Hybrid Securities Investment Fund A Class Fund 860.19 0.77
10 Yinhua CSI Innovation Pharmaceutical Industry ETF Fund 541.12 0.49

5. Concept Sectors

  • Generic Drugs
  • Innovative Drugs
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Social Security Fund Heavy Holdings
  • Fund Heavy Holdings
  • National Team (CICC & Huijin) Holdings
  • Planned Reduction
  • MSCI Mid Cap
  • Non-Cyclical Stocks
  • High Dividend Stocks
  • Zhongchuang 100
  • SME 100
  • SZSE 300
  • Consumption 100
  • CCTV 50
  • SME 300
  • SZSE Innovation Index
  • Innovation 100
  • Pearl River Delta

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information